Butterfly Network, Inc.

NYSE:BFLY

Medical - Devices

Healthcare
$6.08 +32.84%

+$1.88 today

Market cap
$1.63B
Beta
2.20
P/E (TTM)
-25.7
EPS (TTM)
-$0.30
52W Low $1.32High $8.01

Volume 4.78M

Average 4.92M

BFLY Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Butterfly Network, Inc.NYSE: BFLY

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $9.54M fell 3.9% year over year, behind the -3.0% change in trailing-twelve-month research & development. Sequentially, it rose 2.3% from the prior quarter. Over 3 fiscal years it compounded at -25.6% a year.

Context

  • Research & development amounted to 37.1% of revenue in FY2025, down 8.9 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -3.9% toward the trailing-twelve-month pace of -3.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.54M+2.3% QoQ
Last fiscal yearDec 2025
$36.26M-4.1% YoY
LTMMar 2026
$35.88M-3.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.9%——
1 year-4.1%——
3-year CAGR-25.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
36.26M USD
Year-over-year change
-4.1%
4-year CAGR
-16.5%

Research & Development vs competitors

How BFLY compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -3.0% is the 4th highest of 7, against a peer median of -7.4%.
  • Research & development amounts to 34.9% of revenue for BFLY, versus a peer median of 12.8%.
BFLY Competitors
Research & Development for BFLY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARVNArvinas, Inc.LTM Mar 2026$254.4M USD-28.3%-3.5%284.6%
PACBPacific Biosciences of California, Inc.LTM Mar 2026$87.86M USD-27.1%-20.4%54.9%
VALNValneva SELTM Mar 2026€85.57M EUR+12.6%-6.7%54.7%
OFIXOrthofix Medical Inc.LTM Mar 2026$61.4M USD-16.9%+5.2%7.4%
FLGTFulgent Genetics, Inc.LTM Mar 2026$55.69M USD+11.9%+23.1%17.4%
BFLYButterfly Network, Inc.LTM Mar 2026$35.88M USD-3.0%-25.6%34.9%
SIBNSI-BONE, Inc.LTM Mar 2026$17.11M USD+2.1%+8.6%8.3%
AMNAMN Healthcare Services, Inc.LTM Mar 2026$0 USD——0.0%
EVHEvolent Health, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding BFLY) —-7.4%+0.8%12.8%

Competitors are the stored peer set for BFLY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue62.57M73.39M65.9M82.06M97.61M
Cost of Revenue45.51M33.93M49.04M33.23M51.88M
Gross Profit17.05M39.46M16.86M48.83M45.73M
Gross Margin27.3%53.8%25.6%59.5%46.9%
Research & Development74.46M88.04M55.62M37.8M36.26M
Selling, General & Admin135.32M144.44M106.85M85.44M85.11M
Operating Expenses209.78M232.48M162.47M123.24M132.15M
Depreciation & Amortization2.09M5.94M10.57M10.34M8.08M
EBITDA(29.55M)(162.74M)(123.04M)(60.92M)(67.38M)
EBITDA Margin-47.2%-221.8%-186.7%-74.2%-69.0%
Operating Income(192.73M)(193.02M)(145.61M)(74.41M)(86.42M)
Operating Margin-308.0%-263.0%-221.0%-90.7%-88.5%
Interest Income2.57M3.38M7.45M5.02M5.91M
Interest Expense651K2K01.26M1.49M
Other Income / Expenses160.44M24.34M11.99M1.89M9.46M
Income Before Tax(32.29M)(168.68M)(133.62M)(72.52M)(76.95M)
Pre-Tax Margin-51.6%-229.8%-202.8%-88.4%-78.8%
Income Tax Expense121K42K82K(32K)110K
Net Income(32.41M)(168.72M)(133.7M)(72.49M)(77.06M)
Net Margin-51.8%-229.9%-202.9%-88.3%-79.0%
EPS (Basic)(0.19)(0.84)(0.65)(0.34)(0.31)
EPS (Diluted)(0.19)(0.84)(0.65)(0.34)(0.31)
Weighted Avg Shares173.81M199.85M205.39M211.68M247.12M
Weighted Avg Shares (Diluted)173.81M199.85M205.39M211.68M247.12M

Butterfly Network, Inc.

NYSE:BFLY

Intrinsic Alpha fair value

Locked

Current Price

$6.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.